Electroporation and Immunotherapy in Metastatic Colorectal Cancer
Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
The trial is designed as an investigator initiated prospective phase 2 study in patients with
metastatic pMMR colorectal cancer (CRC) to determine the safety and efficacy of calcium
electroporation (CaEP) performed concurrently with irreversible electroporation (IRE)
followed by a PD-1 inhibitor (pembrolizumab).